

PRESS RELEASE  
26 March 2021



## **Mogrify wins Hewitsons Award for Innovation in Business and Price Bailey Award for Business of the Year at CambridgeshireLive Business Excellence Awards 2020**

*Awards recognize potential of Mogrify's technology to accelerate the development of regenerative cell and in vivo reprogramming therapies*

**Cambridge, UK, 26 March 2021:** Mogrify Limited (Mogrify®), a UK company aiming to transform the development of *ex vivo* cell therapies and pioneer the field of *in vivo* reprogramming therapies, was awarded the Hewitsons Award for Innovation in Business and Price Bailey Award for Business of the Year at last night's CambridgeshireLive Business Excellence Awards 2020. The awards recognize the potential of Mogrify's proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular conversion and the maintenance of cell identity, to accelerate the development of regenerative cell and *in vivo* reprogramming therapies.

The Company's technologies, MOGRIFY® and EpiMOGRIFY, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and culture medium conditions required to produce any target cell type from any source cell type.

Mogrify will use these platforms to engineer therapeutic cell types that exhibit efficacy and safety profiles necessary to transform the development of *ex vivo* cell therapies, and pioneer a new class of *in vivo* reprogramming therapies for indications of high unmet clinical need in immuno-oncology, ophthalmology and other disease areas.

Uniquely positioned to address a cellular therapy and regenerative medicine market estimated to be worth in excess of \$39 billion USD by 2023, Mogrify is commercializing its technology via a combination of internal cell and gene therapy development and collaborations. Since February 2019, Mogrify has raised over \$20 million USD in seed and Series A rounds, and \$2.5 million USD in grant funding, and has grown to a headcount of over 60 of scientific, operational, and commercial staff.

The CambridgeshireLive Business Excellence Awards are held annually to celebrate businesses and business people in Cambridgeshire and to promote local entrepreneurship and innovation.

**Pierre-Louis Joffrin, CDO, Mogrify, said:** *"We are honored to have been awarded the Hewitsons Award for Innovation in Business and Price Bailey Award for Business of the Year at the CambridgeshireLive Business Excellence Awards. We have an outstanding team of cellular reprogramming experts at Mogrify and this award is testament to their delivery of scientific, commercial and operational excellence."*

For further information on Mogrify, please visit:

<https://mogrify.co.uk/about-us/>

**ENDS**

## Notes to Editors



*Pierre-Louis Joffrin  
Corporate Development  
Officer, Mogrify*

For high-resolution images please contact Zyme Communications.

### For further information please contact:

#### Mogrify

Darrin M Disley, PhD, OBE

Tel: + 44 (0)1223 734154

Email: [darrin@mogrify.co.uk](mailto:darrin@mogrify.co.uk)

#### Zyme Communications (media inquiries)

Michelle Ricketts, PhD

Tel: +44 (0)7789 053 885

E-mail: [michelle.ricketts@zymecommunications.com](mailto:michelle.ricketts@zymecommunications.com)

#### Westwicke, an ICR Company (investor inquiries)

Stephanie Carrington

Tel: +1 (646) 277-1282

Email: [stephanie.carrington@icrinc.com](mailto:stephanie.carrington@icrinc.com)

*To opt-out from receiving press releases from Zyme Communications please e-mail [info@zymecommunications.com](mailto:info@zymecommunications.com). To view our privacy policy, please [click here](#).*

### About Mogrify [www.mogrify.co.uk](http://www.mogrify.co.uk)

Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular conversion (Rackham *et al.*, Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj *et al.*, Cell Systems, 2020). The platforms, MOGRIFY® and EpiMOGRIFY, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors (or small molecules) and optimal culture conditions required to produce any target human cell type from any source human cell type.

The platform can be used to enhance existing stem-cell forward reprogramming methods or can bypass development pathways altogether, affecting a direct transdifferentiation between a mature cell type to another mature cell type.

Mogrify is applying its proprietary and award-winning platforms to engineer a renewable and scalable source of cell types that exhibit efficacy and safety profiles necessary to transform the development of *ex vivo* cell therapies and pioneer a new class of *in vivo* reprogramming therapies for indications of high unmet clinical need in immuno-oncology, ophthalmology and other disease areas.

Uniquely positioned to address a regenerative medicine market estimated to be worth \$39 billion USD by 2023, Mogrify is commercializing its technology via a combination of internal cell and gene therapy development, co-development partnerships, and out-licensing of novel cell conversions. Based in Cambridge, UK, the Company has raised over \$20 million USD funding from Ahren Innovation Capital, Parkwalk, 24Haymarket, Dr. Darrin M. Disley, OBE and the University of Bristol Enterprise Fund III.

Follow Mogrify on Twitter [@Mogrify\\_UK](#) and LinkedIn [@Mogrify](#)